AACR Annual Meeting 2018 | Chicago, USA

Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018.

Presentation and poster details have been released on the AACR website and include:

• Next generation immunotherapies: targeting innate lymphocytes and tumor microenvironment

Session Type: Meet-the-Expert Session

Track(s): Immunology, experimental and molecular therapeutics

Session Date and Time: Monday Apr 16, 2018 7:00 AM – 8:00 AM

Location: McCormick Place South, Level 4, Room S406 (Vista Ballroom)

Speaker: Eric Vivier, Chief Scientific Officer, Innate Pharma

 

• Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, and cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy

Session Title: Phase I/II, II, and III Trials in Progress

Session Date and Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM

Location: McCormick Place South, Hall A, Poster Section 42

Poster Board Number 10

Abstract: CT158

See poster

 

• NKG2A immune checkpoint blockade potentiates cetuximab induced ADCC in head and neck cancer preclinical model

Session Category: Immunology

Session Title: Immune Checkpoints 1

Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 31

Poster Board Number 15

Abstract: 1690

See poster

 

• Combination of monalizumab and durvalumab as a potent immunotherapy treatment for solid human cancers

Session Category: Immunology

Session Title: Immune Checkpoints 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number 6

Abstract: 2714

See poster

 

• Preclinical development of humanized CD39 and CD73 blocking antibodies targeting the ATP/Adenosine immune checkpoint pathway for cancer immunotherapy                                                                                              

Session Category: Immunology

Session Title: Immune Checkpoints 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number 10

Abstract: 2718

See poster

 

• Preclinical development of first-in-class antibodies targeting Siglec-9 immune checkpoint for cancer immunotherapy

Session Category: Immunology

Session Title: Immune Checkpoints 2

Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 32

Poster Board Number 5

Abstract: 2713

See poster